University of Maryland School of Medicine's (UM SOM) Centre for Vaccine Development (CVD) along with CVD-Mali and the Ministry of Health of Mali have commenced a clinical trial of Ebola vaccine on health care workers in Mali, West Africa.
The trial follows two months of effort by a consortium led by the World Health Organisation (WHO) to bring this vaccine into clinical studies in West Africa.
The consortium includes the VRC, the Jenner Institute at the University of Oxford, the CVD-UM SOM and CVD-Mali, GlaxoSmithKline (GSK) Biologicals and the Wellcome Trust.
Developed by the Vaccine Research Centre (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, the vaccine consists of an adenovirus (cold virus) that develops a single attachment protein of Ebola virus in humans without creating any harm to human body.
Centre for Vaccine Development (CVD) director Myron Levine said: "This research will give us crucial information about whether the vaccine is safe, well tolerated and capable of stimulating adequate immune responses in the highest priority target population, health care workers in West Africa.
"If it works, in the foreseeable future it could help alter the dynamic of this epidemic by interrupting transmission to health care and other exposed front-line workers."